Missing: Modules for Novel Diagnostics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Modules for Novel Diagnostics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Modules for Novel Diagnostics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Modules for Novel Diagnostics is included in 1 Expert Collection, including Health Monitoring & Diagnostics.
Health Monitoring & Diagnostics
Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting
Modules for Novel Diagnostics Frequently Asked Questions (FAQ)
When was Modules for Novel Diagnostics founded?
Modules for Novel Diagnostics was founded in 2004.
Who are Modules for Novel Diagnostics's competitors?
Competitors of Modules for Novel Diagnostics include Ikonisys, Binx Health, SomaLogic, LineaGen Research, Intellirod Spine, HyperMed Imaging, Molecular Detection, Vivacta, Micronics Microfluidics, Celerus Diagnostics and 19 more.
Compare Modules for Novel Diagnostics to Competitors
AndroDx (Andro Diagnostics) is a medical device maker focused on making more accurate diagnostic tests for prostate cancer.
At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.
Quadraspec is changing the face of diagnostic medicine. Quadraspec's patented SDI label-free detection technology aims to permit the rapid analysis of up to 100 unique tests on up to 1,000 unique patients per hour. Quadraspec's , multiplex-capable diagnostics platform aims to allow high throughput, label-free, highly sensitive bioassays, and diagnostics.
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.
NIR Diagnostics is developing a diagnostic device to quantitatively assess the progress of the wound healing process. Per the company, the device has the potential to be a more accurate, more rapid, and less expensive method of wound assessment compared to those currently on the market.
Binx Health is an in vitro diagnostics Point-of-Care (POC) company that provides at-home STI testing. The platform also includes evidence-based testing, counseling, treatment, and follow up in order to increase screening and reduce infections.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.